JP2013540771A5 - - Google Patents

Download PDF

Info

Publication number
JP2013540771A5
JP2013540771A5 JP2013533235A JP2013533235A JP2013540771A5 JP 2013540771 A5 JP2013540771 A5 JP 2013540771A5 JP 2013533235 A JP2013533235 A JP 2013533235A JP 2013533235 A JP2013533235 A JP 2013533235A JP 2013540771 A5 JP2013540771 A5 JP 2013540771A5
Authority
JP
Japan
Prior art keywords
insulin
terminal
pharmaceutical composition
terminally modified
modified insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013533235A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013540771A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/068019 external-priority patent/WO2012049307A2/en
Publication of JP2013540771A publication Critical patent/JP2013540771A/ja
Publication of JP2013540771A5 publication Critical patent/JP2013540771A5/ja
Withdrawn legal-status Critical Current

Links

JP2013533235A 2010-10-15 2011-10-14 新規n末端修飾インスリン誘導体 Withdrawn JP2013540771A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10187706.6 2010-10-15
EP10187706 2010-10-15
US39409010P 2010-10-18 2010-10-18
US61/394,090 2010-10-18
PCT/EP2011/068019 WO2012049307A2 (en) 2010-10-15 2011-10-14 Novel n-terminally modified insulin derivatives

Publications (2)

Publication Number Publication Date
JP2013540771A JP2013540771A (ja) 2013-11-07
JP2013540771A5 true JP2013540771A5 (cg-RX-API-DMAC10.html) 2014-11-20

Family

ID=43638785

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013533235A Withdrawn JP2013540771A (ja) 2010-10-15 2011-10-14 新規n末端修飾インスリン誘導体

Country Status (5)

Country Link
US (1) US20140315797A1 (cg-RX-API-DMAC10.html)
EP (1) EP2627670A2 (cg-RX-API-DMAC10.html)
JP (1) JP2013540771A (cg-RX-API-DMAC10.html)
CN (1) CN103154024A (cg-RX-API-DMAC10.html)
WO (1) WO2012049307A2 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
EP2836508B1 (en) 2012-04-11 2016-06-29 Novo Nordisk A/S Insulin formulations
AU2015349890B2 (en) * 2014-11-21 2018-08-30 Merck Sharp & Dohme Llc Insulin receptor partial agonists
CN108368163A (zh) * 2015-08-25 2018-08-03 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
BR112018002416A2 (pt) * 2015-08-25 2018-09-18 Novo Nordisk As derivados de insulina e seus usos médicos
EP3341401A1 (en) * 2015-08-25 2018-07-04 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
CN114656378A (zh) * 2016-05-16 2022-06-24 得克萨斯州大学系统董事会 阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质
ES2886837T3 (es) 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina
CA3071686A1 (en) 2017-08-17 2019-02-21 Novo Nordisk A/S Novel acylated insulin analogues and uses thereof
TW202039437A (zh) 2018-12-11 2020-11-01 法商賽諾菲公司 肽黏合劑
TWI717245B (zh) * 2019-03-29 2021-01-21 丹麥商諾佛 儂迪克股份有限公司 葡萄糖敏感型胰島素衍生物
MA58093B1 (fr) 2019-12-11 2024-09-30 Novo Nordisk A/S Nouveaux analogues d'insuline et leurs utilisations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ273285A (en) * 1993-09-17 1997-10-24 Novo Nordisk As Insulin derivatives and compositions thereof
AU2004261353B2 (en) 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
ES2435522T3 (es) * 2005-02-02 2013-12-20 Novo Nordisk A/S Derivados de insulina
CN101180081B (zh) 2005-05-25 2015-08-26 诺沃-诺迪斯克有限公司 稳定的多肽制剂
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
EP2514406A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
AU2008288413B2 (en) * 2007-08-15 2013-09-26 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
CN102149411A (zh) * 2008-09-12 2011-08-10 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
EP2344200A2 (en) 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
CN102227213A (zh) 2008-11-28 2011-10-26 诺沃—诺迪斯克有限公司 适合于衍生化的胰岛素肽的口服施用的药物组合物
BR112012016853A2 (pt) 2010-01-12 2017-10-17 Novo Nordisk As "composições farmacêuticas para administração oral de peptídeos de insulina".

Similar Documents

Publication Publication Date Title
WO2011153493A3 (en) Biodegradable lipids for the delivery of active agents
MX2014014902A (es) Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
WO2008137758A3 (en) Amino acid lipids and uses thereof
EP4286012A3 (en) Compounds and compositions for intracellular delivery of therapeutic agents
PE20171095A1 (es) Acidos grasos novedosos y su uso en la conjugacion con biomoleculas
EP2810661A3 (en) Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
EP4410317A3 (en) Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2011141705A8 (en) Novel cationic lipids and methods of use thereof
EP4332576A3 (en) Synergistic enhancement of the delivery of nucleic acids via blended formulations
NZ602557A (en) Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2014014613A3 (en) Self-assembling peptides, peptide nanostructures and uses thereof
EP4241767A3 (en) Novel lipids and compositions for the delivery of therapeutics
WO2015184256A3 (en) Biodegradable lipids for delivery of nucleic acids
EP2871180A4 (en) 2-AMINONICOTINIC ETER DERIVATIVE AND BACTERICIDE THEREFOR AS ACTIVE SUBSTANCE
WO2012054500A3 (en) Compositions for drug administration
WO2008052173A3 (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
WO2015048498A3 (en) Carrier-free biologically-active protein nanostructures
EP3760638A3 (en) Compositions and methods utilizing lysophosphatidylcholine scaffolds
EP3037417A3 (en) 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
WO2013096958A8 (en) Compositions and methods for the delivery of biologically active rnas
Muthukumarasamyvel et al. Hierarchical self-assembly of bile-acid-derived dicationic amphiphiles and their toxicity assessment on microbial and mammalian systems
EP2928462A4 (en) METHOD FOR ADMINISTERING COMPOUNDS WITH DOCOSAPENTAIC ACID
RU2015140996A (ru) Топическая противомикробная дерматологическая композиция
WO2010080754A3 (en) Nanoparticle pharmaceutical formulations
WO2011143271A3 (en) Therapeutic liposomes and methods for producing and using the same